Curriculum Vitae: Dr Andrea Ardizzoni

STUDY	
10/82	Degree in Medicine and Surgery "cum laude" at University of Genoa
3/85	Training at Bone Marrow Transplant Unit, Centre Leon Berard, Lion.
7/85	Specialty in Oncology at University of Genoa.
4/88	Training on "Biological Response Modifiers" at the Netherland Cancer Institute,
	Amsterdam.
12/90	"European Certification in Medical Oncology"
6/91	Specialty in Internal Medicine at University of Genoa
11/92-5/93	Fellowship, Department of Medicine, Brown University, Prividence R.I. (USA)
4/97	U.T.M.D.Anderson Cancer Center Clinical Exchange Program
10/00-4/01	Health Management Course "Ippocrate" at Bocconi University
until 2017	Participation into several courses regarding design, conduct and reporting of Clinical
	Trials including a number of recent trainings on "Good Clinical Practice" validated
	by Transcelerate BIOPHARMA.INC (last one performed on 28/7/16)
CAREER	
3/87-6/94	Full time assistant, division of Medical Oncology 1, Institute for Cancer Research,
	Genoa.
7/94-12/03	Full time deputy head division of Medical Oncology 1, Institute for Cancer Research,
	Genoa.
10/96-12/03	Contract Professor, Medical School, University of Genoa
7/02-12/03	Coordinator Lung Cancer Program, Institute for Cancer Research, Genoa.
01/04-07/14	Head Medical Oncology, University Hospital, Parma
01/04-07/14	Contract Professor, Medical School, University of Parma
from 7/14	Head Medical Oncology, University Hospital, Bologna
from 2/17	Full Professor Medical Oncology Alma Mater Studiorum, Bologna University

PROFESSIONAL CURRICULA (Clinical and research activity)

until 2003 Clinical activity at Medical Oncology Unit, National Institute for Cancer Research, Genoa as assistant and deputy head

-01/04-07/14 Head Medical Oncology Unit, University Hospital, Parma. The Unit includes 14 medical oncologists, 8 oncology fellows and 6 biologists. The Unit follows around 4000 patients (around 1000 new patients/year). The Unit has a 20-bed ward (approximately 800 admissions/year) and a 20-bed out-patient clinic (approximately 1000 admissions/year and 100 patients seen/day). The Unit has been recognized as an "ESMO Designated Center in the Integration of Oncology and Palliative Care"

The Unit has nearly 30 clinical trials/year running with approximately 100 patients enrolled every year.

- -07/14-present Head Medical Oncology Unit, University Hospital, Bologna. The Unit includes 7 medical oncologists, 6 oncology fellows and 4 data-managers. The Unit follows around 1000 new patients/year. The Unit has a 24-bed ward (approximately 1000 admissions/year) and a 20-bed out-patient clinic (approximately 1000 admissions/year and 50 patients seen/day). The Unit has been recognized as an "ESMO Designated Center in the Integration of Oncology and Palliative Care" The Unit has nearly 60 clinical trials/year open to accrual.
- -1995-96 Recipient of **AIRC** (**Italian Association for Cancer Research**) **grant** (45000 Euro) for the project: "Chemotherapy and radiotherapy, sensitized with low dose cisplatin, in patients with inoperable stage III NSCLC
- -1994-96 Recipient of **Italian Minister of Health grant** (230.000 Euro) for the project "Verifica del ruolo di nuove metodiche di biologia cellulare e molecolare nella prevenzione, diagnosi precoce e terapia di tumori pleuro-polmonari"
- -2007 Recipient of **Italian Minister of Health grant** (296.000 Euro) for the project: "Biological predictive factors of response to targeted therapies in lung cancer"
- -2007 Recipient of **AIFA** (**Italian Drug Agency**) **grant** (240.000 Euro) for the study: "Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first line treatment in extensive stage small cell lung cancer"
- -2009 Recipient of **AIRC** (Italian Association for Cancer Research) grant (360.000 Euro) for the project: "Optimizing EGFR inhibitor treatment in Non-Small Cell Lung Cancer"
- -2013 Recipient of **AIRC** (Italian Association for Cancer Research) grant (360.000 Euro) for the project: "Novel molecularly targeted approaches in the treatment of squamous cell cancer of the lung"
- -2016 Recipient of **AIRC** (**Italian Association for Cancer Research**) **grant** (477.000 Euro) for the project: "Study of PD-L1 and other immunotherapy efficacy predictors on cytology and circulating tumor cells in advanced NSCLC"
- -until 12/16 Co-Author of approximately **300 scientific papers** published on peer-reviewed international journals for a total **"impact factor" of around 1000** and **total H-index of 44**
- -until 12/16 Participation to around **500 courses** or congresses of which approximately 400 as speaker/chairman
- -until 12/16 Principal Investigator in approximately 150 international studies

Main Appointments

- -Past Chemotherapy Chairman EORTC Lung Group
- -Past Secretary EORTC Lung Group

-Past Chairman Quality Assurance Committee EORTC Lung Group

-Past Member of Gruppo di Lavoro della Presidenza del Consiglio dei Ministri "Linee guida inerenti l' uso di prodotti di terapia genica"

- -2005-2015 Secretary of GOIRC cooperative group
- -from 2009 Member of Istituto Tumori Toscano International Scientific Committee
- -2011-2014 Member of Parma University Hospital Research Board
- -from 2012 Member of S.Martino University Hospital- Genoa National Institute for Cancer Research Advisory Committee
- -from 2015 Menber of Scientific Committee Istituto Scientifico Romagnolo per la Ricerca e Cura dei Tumori
- -from 2015 Member Educationl Committee IASLC

12/7/17

hoher Artin